Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Impact Biomedical's Business Segments
Impact Biomedical's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Biotech Retail Sales
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Biotech Retail Sales0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Biotech Retail Sales | $ 0 | - |
Revenue by Product & Service Category - FY
- Biotech Retail Sales100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Biotech Retail Sales | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Biotech Retail Sales0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Biotech Retail Sales | $ 0 | - |
Description of Impact Biomedical
Impact Biomedical Inc. (IBO) focuses on discovering, confirming, and patenting scientific innovations and technologies for human healthcare and wellness. The company collaborates with external partners through licensing, co-development, joint ventures, and other relationships. Its product offerings include biopharmaceuticals, over-the-counter wellness products, and drug discovery targeting neurological, oncologic, and inflammatory diseases. IBO operates primarily through its subsidiaries: Global BioLife, Inc., Impact BioLife Science, Inc., Global BioMedical, Inc., and Sweet Sense, Inc.
Key proprietary technologies include Linebacker, a platform of small molecule polyphenol compounds for oncology, inflammatory disorders, and neurology; Laetose™, a patented formulation designed to reduce caloric intake and glycemic index with potential applications in metabolic and inflammatory diseases; Functional Fragrance Formulation (3F), a suite of botanical ingredient-based fragrances with antimicrobial and additive uses; and Equivir/Equivir G, a blend of polyphenols with antiviral effects licensed to ProPhase Laboratories.
IBO actively seeks partners for the development and commercialization of its technologies worldwide and continually evaluates emerging technologies in biopharmaceuticals, indoor air quality, preservatives, bioplastics, personalized medicine, nanotechnology, cannabis products, and pain management. In 2025, the company expanded its intellectual property portfolio to over 60 issued and 60 pending patents, including the allowance of the Laetose patent in Europe.
Impact BioMedical, Inc. operates in a single business segment: Biotechnology. The company focuses on research, development, and commercialization of medical and pharmaceutical solutions addressing unmet medical needs. Impact BioMedical advances drug discovery targeting neurological, oncology, and immunological diseases through technology and strategic partnerships. Additionally, the company develops alternative sugar products for diabetes management and functional fragrance formulations for industrial and medical applications.